Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pricing & Reimbursement

Set Alert for Pricing & Reimbursement

Ease The Pain – Making Payment Models, Tech, Integration Work For Patients

Multiple payment models, including differential pricing for pooled purchases, and technology-based healthcare platforms are some of the ways to build a patient-centric ecosystem said officials from Roche, VCs and non-government bodies at a recent conference

Commercial Business Strategies

Immuneel COO On Benchmarking The Firm’s CAR-T Against Mature, Global Data Sets

Immuneel’s COO, Dr Arun Anand, talks to Scrip about how things are shaping for the Indian start-up’s autologous CD19 directed CAR-T cell therapy and the ‘journey to be traversed’ on the pricing front. He believes India could potentially see cell therapies being commercialized in the next 12 to 18 months.

Commercial Personalized Medicine

Sanofi Joins Peers, Will Make Lantus Available At $35 For All US Patients

Sanofi is the last of three big insulin makers to offer its top-selling insulin at the same out-of-pocket cost regardless of patients’ insurance coverage, but calls for other health care players to make concessions as well.

Market Access Pricing Strategies

Novo Nordisk Lowers Some Insulin List Prices, Following Lilly’s Lead

The company will lower the US list price of Levemir, NovoLog and certain other branded insulins by 65-75% and will also lower some unbranded insulin prices effective January 2024. Tresiba is not included.

Metabolic Disorders Pricing Strategies

Leqembi Coverage By Veterans Affairs Department Sign Of Success For Eisai’s Payer Engagement Strategy

Alzheimer’s product is following a different playbook than Aduhlem, reflecting better data – and hard-earned lessons. Eisai estimates that 80-90% of veterans who are eligible for Leqembi treatment based on the FDA label would also fit the VA’s criteria.

Government Payers Medicare

Both Pfizer And GSK RSV Vaccines Set For Approval – But Could Next Readouts Give One The Edge?

The two frontrunners look set to gain US FDA approval, but will need more robust long-term data to convince frontline physicians and payers of benefits to at-risk individuals.

Advisory Committees Commercial

IRA Drug Pricing Implications Impact Pharma Views On Deal Terms, Valuations

Pharma business development executives and venture capital investors shared their thoughts on the Inflation Reduction Act at Biocom’s Global Life Science Partnering and Investor Conference in San Diego.

Deals Financing

‘Inertia’ Likely To Restrain Biosimilar Humira In US Market, Experts Say

PBM contracting and payer formulary placement for branded Humira signal headwinds for biosimilar versions in the US, according to participants in an IQVIA-sponsored panel.

Biosimilars Market Access

Lilly’s Insulin Cost Cutting Plan: Replacing Rebates With Cost Sharing Help At Point Of Sale

Biden Administration praises Lilly for latest moves to improve affordability of insulin in private market and calls for other sponsors to follow suit. Lilly’s plan is also tactical, as manufacturers of highly-rebated drugs with serial price hikes face an increased rebate liability in Medicaid next year.

Reimbursement Pricing Strategies

ICER’s Leqembi Assessment Inches Higher, Still Sees Eisai Price As Too High

The drug pricing watchdog said in its revised report that Alzheimer’s therapy Leqembi (lecanemab) meets cost-effectiveness thresholds at $8,900-$21,500, below Eisai/Biogen’s $26,500 list price.

Cost Effectiveness Pricing Strategies

No AdComm Puts Sarepta On Path To Blockbuster Success With Duchenne Gene Therapy

The US FDA’s waiving of an advisory committee is another promising signal that Sarepta's Duchenne gene therapy SRP-9001 could be approved on 29 May and set it up to become a bigger earner than Novartis’s Zolgensma.

Companies Commercial

Zuranolone Launch Requires Sage To Shift The Way Doctors Treat Depression

CEO Barry Greene and team spoke with Scrip about Sage and Biogen’s focus on short-term, episodic dosing, and said doctors and payers – pending zuranolone’s approval – are responding to the sales pitch.

Launches Neurology
See All
UsernamePublicRestriction

Register